Maternal serum lamin A can enable the prediction of adverse pregnancy outcomes

Key clinical point: Maternal serum lamin A (LMNA) could emerge as a potential biomarker for prenatal diagnosis of fetal congenital heart disease (CHD), neural tube defects (NTD), and preeclampsia (PE).

Major finding: Significantly lower LMNA levels were observed in pregnancies with fetal CHD, NTD, and PE (all P < .0001). The areas under the receiver operating characteristic curve for LMNA in prenatal diagnoses of CHD, NTD, early-onset PE, and late-onset PE were 0.875, 0.871, 0.851, and 0.674, respectively.

Study details: The data are derived from a prospective study including 2711 singleton pregnant women at 15-18 weeks of gestation who underwent measurement of serum LMNA levels.

,

Disclosures: The study was funded by the National Key Research and Development Program and National Natural Science Foundation of China, among others. The authors reported no conflicts of interest.

Source: Chen L et al. Maternal serum lamin A is a potential biomarker that can predict adverse pregnancy outcomes. EBioMedicine. 2022;77:103932 (Mar 11). Doi: 10.1016/j.ebiom.2022.103932